๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Seoul
Clinical trial register · South Korea

Clinical Trials in Seoul, 2026

Every study on the ClinicalTrials.gov registry that lists a site in South Korea and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 3364 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:49 UTC
3364
Studies in scope
all four open statuses
1829
Recruiting now
open to new participants
503
Lead sponsors
across recruiting studies
Top sites
Seoul 2820 Daegu 550 Seongnam-si 485 Busan 464 Goyang-si 395
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca195 Seoul National University Hospital187 Yonsei University147 Samsung Medical Center142 Merck Sharp & Dohme LLC112
Site location
Seoul2820 Daegu550 Seongnam-si485 Busan464 Goyang-si395
All 252 locations
Target enrolment
to

Trials with a site in Seoul

2820 of 3364 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in South Korea
Start
Active, closed
To Evaluate the Safety and Pharmacokinetic Characteristics of AJU-C714 and C714R in Healthy Adults
NCT06933459Dyslipidemia
AJU Pharm Co., Ltd.
Phase 1
60
Seoul
2025-05-24
Recruiting
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
NCT06952504Endometrial Cancer
DrugsSacituzumab tirumotecan·Docetaxel·Paclitaxel·Cisplatin
Merck Sharp & Dohme LLC
Phase 3
1,123
Gyeonggi-do, Daegu, Seoul
2025-05-22
Recruiting
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)
NCT06962800Primary Membranous Nephropathy
DrugsFelzartamab·Tacrolimus
Biogen
Phase 3
180
Suwon, Seoul, Busan
2025-05-22
Not yet open
To Evaluate Effect of Food of DA-5222 in Healthy Adult Subjects
NCT06993168Healthy
DrugDA-5222
Dong-A ST Co., Ltd.
Phase 1
32
Seoul
2025-05-21
Active, closed
A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)
NCT06966479Severe Asthma
DrugVerekitug
Upstream Bio Inc.
Phase 2
396
Daegu, Seoul, Taebuk
2025-05-21
Recruiting
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
NCT06876649Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma
DrugPirtobrutinib
Eli Lilly and Company
Phase 4
787
Seoul
2025-05-20
Recruiting
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
NCT06935370Heart Failure
DrugsVicadrostat·Dapagliflozin
Boehringer Ingelheim
Phase 3
4,200
Busan, Gwangju, Incheon, Seongnam, Seoul, Wลnju
2025-05-20
Recruiting
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma
NCT06977581Asthma
DrugTilrekimig
Pfizer
Phase 2
252
Jeonju, Daegu, Seoul
2025-05-20
Recruiting
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
NCT06876662Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma
DrugPirtobrutinib
Eli Lilly and Company
Phase 4
279
Seoul
2025-05-20
Recruiting
Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)
NCT06711887Lupus Nephritis
DrugIanalumab
Novartis Pharmaceuticals
Phase 3
348
Suwon, Seoul
2025-05-19
Recruiting
Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation
NCT06830798Delayed Graft Function, DGF, Kidney Transplant
DrugRavulizumab
Alexion Pharmaceuticals, Inc.
Phase 3
450
Gyeonggi-do, Seoul
2025-05-19
Active, closed
Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)
NCT06898957Small Cell Lung Cancer
DrugsTarlatamab·Durvalumab
Amgen
Phase 1
29
Seoul
2025-05-16
Recruiting
Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
NCT06947993Atopic Dermatitis
Novartis Pharmaceuticals
Phase 2
224
Ansan, Seoul
2025-05-16
Not yet open
Investigations of Factors Associated With Treatment Response and Prognosis in Anxiety Disorders
NCT06773585Panic Disorder
Kangbuk Samsung Hospital
Observational
185
Seoul
2025-05-15
Recruiting
Optimizing Reperfusion to Improve Outcomes and Neurologic Function
NCT06990867Acute Ischemic Stroke
Corxel Pharmaceuticals
Phase 2/3
740
Seoul
2025-05-15
Active, closed
A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone
NCT06806852Head and Neck Squamous Cell Carcinoma
DrugsBI 770371·Cetuximab·Pembrolizumab
Boehringer Ingelheim
Phase 1
91
Seoul, Suwon
2025-05-14
Recruiting
A proof-of Concept Study to Assess Safety and Tolerability of HM15421/GC1134A in Patients With Fabry Disease
NCT06858397Fabry Disesase
GC Biopharma Corp
Phase 1/2
18
Yangsan, Seoul
2025-05-14
Recruiting
The Effect of Mobile Robot Assisted Gait Training on Gait Performance in Chronic Patients With Impaired Gait Function After Burn Injury
NCT07277166Burns, Gait Dysfunction, Robot Training
Hangang Sacred Heart Hospital
Not applicable
20
Seoul
2025-05-13
Recruiting
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
NCT06925737Prostate Cancer, Prostatic Neoplasms
DrugsIfinatamab Deruxtecan·Prednisone·Docetaxel
Merck Sharp & Dohme LLC
Phase 3
1,440
Hwasun Gun, Seocho-gu, Songpagu, Tonggu, Seoul
2025-05-13
Recruiting
Clinical Trial for Safety and Effectiveness Evaluation of Tarlatamab (AMG757) With Etoposide, Carboplatin and Atezolizumab in Transformed Small Cell Lung Cancer Patients From Adenocarcinoma After EGFR TKI Treatment
NCT06830694Small Cell Carcinoma of Lung
Sehhoon Park
Phase 2
50
Seoul
2025-05-13
Active, closed
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION)
NCT06925750Pulmonary Arterial Hypertension
DrugSotatercept
Merck Sharp & Dohme LLC
Phase 2
130
Gwangju, Seogu, Seoul
2025-05-12
Recruiting
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
NCT06819891Moderately to Severely Active Crohns Disease
DrugAfimkibart
Hoffmann-La Roche
Phase 3
425
Ansan-si, Daegu, Gwangju, Seoul
2025-05-12
Recruiting
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
NCT06563895Amyloidosis, Amyloid Cardiomyopathy, Transthyretin Amyloidosis, Cardiomyopathies
DrugAcoramidis
Eidos Therapeutics, a BridgeBio company
Phase 3
587
Seoul
2025-05-12
Recruiting
Comparison of Moderate-Intensity Statin Plus Ezetimibe vs. High-Intensity Statin for Coronary Plaque Stabilization
NCT06767345Coronary Artery Disease, Atherosclerosis of Coronary Artery, Plaque, Atherosclerotic
Korea University Anam Hospital
Phase 4
408
Seoul
2025-05-12
By invitation
Comparison of First Attempt Success in Nasotracheal Intubation Using Macintosh Videolaryngoscope vs. Flexible Bronchoscope
NCT06964295Intubation Complication
Seoul National University Hospital
Not applicable
74
Seoul
2025-05-09
Recruiting
ID93+GLA-SE Vaccine Against Tuberculosis in Older Adults Aged 55-74
NCT06714513Tuberculosis, Pulmonary
Quratis Inc.
Phase 1
144
Gwangmyeong, Seoul, Suwon
2025-05-09
Recruiting
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
NCT06935357Immunoglobulin A Nephropathy (IgAN)
DrugFelzartamab
Biogen
Phase 3
454
Busan, Anyang-si, Seongnam-si, Suwon, Seoul
2025-05-08
Recruiting
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
NCT06881784NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma)
DrugsCetuximab·Docetaxel
Revolution Medicines, Inc.
Phase 3
590
Gyeonggi-do, Cheongju-si, Hwasun, Seoul
2025-05-06
Recruiting
A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2)
NCT06952699Narcolepsy Type 2
DrugTAK-360
Takeda
Phase 2
88
Junggu, Suwon, Seoul
2025-05-06
Recruiting
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
NCT06499285Myelodysplastic Syndromes
DrugElritercept
Takeda
Phase 3
225
Daegu, Seoul
2025-05-06
Recruiting
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
NCT06921785Hepatocellular Carcinoma
DrugsRilvegostomig·Tremelimumab·Atezolizumab·Bevacizumab
AstraZeneca
Phase 3
1,220
Busan, Goyang-si, Gyeonggi-do, Seongnam-si, Seoul
2025-05-06
Recruiting
Left Bundle Branch Versus Minimized Ventricular Pacing in Patients With Sick Sinus Syndrome and Prolonged AV Interval
NCT07314008Sick Sinus Syndrome, Atrioventricular Nodal Dysfunction
Asan Medical Center
Not applicable
440
Seoul
2025-05-02
Recruiting
Assessment of Safety and Efficacy of Poteligeo Inj. 20 mg (Mogamulizumab) Through Use-result Surveillance
NCT07132567Mycosis Fungoides, Sezary Syndrome
DrugMogamulizumab
Kyowa Kirin Co., Ltd.
Observational
15
Busan, Seoul
2025-05-02
Recruiting
Presepsin Diagnostic Performance in Severe Burn Sepsis
NCT07060560Sepsis, Burns
Dohern Kym
Observational
138
Seoul
2025-05-01
Not yet open
Clinical Trial for the Validation of AR Based Neuronavigation System
NCT05776706Brain Neoplasms, Cerebral Aneurysm, Cerebral Arteriovenous Malformation, Navigation, Spatial
Seoul National University Hospital
Not applicable
80
Seoul
2025-05-01
Recruiting
SMC Radiation Oncology SABR Cohort for Oligometastasis
NCT07121335Stereotactic Body Radiation Therapy (SBRT), Oligometastasis, Oligoprogression, ctDNA
Samsung Medical Center
Observational
60
Seoul
2025-05-01
Recruiting
A Study of Lorigerlimab in Participants With Advanced Solid Tumors
NCT06730347Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Clear Cell Adenocarcinoma of Ovary
MacroGenics
Phase 2
80
Goyang-si, Seongnam-si, Seoul
2025-05-01
Recruiting
Prospective Multicenter Registry of Patients With Mitral Stenosis Undergoing Percutaneous Mitral Balloon Commissurotomy
NCT07175532Mitral Stenosis
Asan Medical Center
Observational
400
Seoul
2025-05-01
Not yet open
An Open-label, Single-arm, Multicenter Phase II Study to Evaluate the Efficacy of Amivantamab in Combination With FOLFIRI as a Second-line Treatment in Patients With RAS/BRAF Wild-type Advanced Colorectal Cancer Progressing on Prior Anti-EGFR Based Treatment.
NCT06855849RAS/BRAF Wild-type Advanced Colorectal Cancer Patients
DrugsAmivantamab·Folfiri
Yonsei University
Phase 2
85
Seoul
2025-05
Not yet open
The Food Effect on PK Characteristics and Safety Profiles of PA-111
NCT06976489Mixed Dyslipidemia
DrugPA-111
Addpharma Inc.
Phase 1
40
Seoul
2025-05
Not yet open
Optimizing Radiation Dose and Utilizing Wearable Devices to Reduce Arrhythmia Risk in Patients Undergoing Thoracic Radiotherapy: A Prospective Cohort Study
NCT06897189Cardiotoxicity, Thoracic Radiotherapy, Wearable Electronic Devices, Thoracic Neoplasms
Yonsei University
Observational
111
Seoul
2025-05
Not yet open
Evaluate Safety and Tolerability of RX001 in Patients With KRAS Mutant Advanced NSCLC
NCT06934590Non-Small Cell Lung Cancer
GeneCraft Inc.
Phase 1
18
Seoul
2025-05
Not yet open
Effect of End-inspiratory Pause on Gas Exchange During Mediastinal Mass Excision With CO2 Insufflation and One-lung Ventilation
NCT06956079Mediastinal Mass Requiring Video-assisted Surgical Excision
Yonsei University
Not applicable
58
Seoul
2025-05
By invitation
The Efficacy and Safety of Herbal Medicine Treatment for Obese Patients With Spinal and Joint Pain
NCT06859697Obesity and Overweight
Jaseng Medical Foundation
Not applicable
40
Seoul
2025-04-30
By invitation
Evaluation of 'RUS NE' in Robot-Assisted Partial Nephrectomy: Efficacy, Safety, and Stability
NCT06945640Kidney Neoplasm, Nephrectomy, Surgical Navigation Systems, Renal Mass
Hutom Corp
Not applicable
80
Seoul
2025-04-30
Recruiting
A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer
NCT06926920Triple Negative Breast Cancer
DrugSacituzumab Govitecan
Gilead Sciences
Phase 1/2
100
Seoul
2025-04-30
Recruiting
A Multicenter Study of RUS NE
NCT06868186Renal Tumors
Hutom Corp
Not applicable
204
Kwangju, Seoul
2025-04-29
Recruiting
Determinants of Rescue Ventilation Requirement in Airway Surgery Under General Anesthesia With THRIVE
NCT06925282Subglottic Stenosis (SGS)
Seoul National University Hospital
Observational
80
Seoul
2025-04-25
Recruiting
Same-day Radioembolization for Large HCC
NCT06944483Hepatocellular Carcinoma (HCC)
Seoul National University Hospital
Observational
138
Goyang, Seoul
2025-04-25
Recruiting
Head and Neck Cancer Omics/Integrated Precision Medicine (HOPE)
NCT07190573Head and Neck Cancer
Samsung Medical Center
Observational
350
Seoul
2025-04-25
Recruiting
Comparison of Pitavastatin Plus Ezetimibe Versus High-Intensity Statin Therapy on Risk of New-Onset Diabetes Mellitus
NCT06767774ASCVD, Diabetes, Statin
DrugHigh-intensity statin
Korea University Anam Hospital
Phase 4
2,000
Seoul
2025-04-25
Recruiting
Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
NCT06915753Metastatic Hepatocellular Carcinoma, Solid Tumors, Solid Tumor, Adult, FGFR Gene Amplification
Tyra Biosciences, Inc
Phase 1
125
Seoul
2025-04-24
Recruiting
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
NCT06875310Carcinoma, Non-Small-Cell Lung
DrugsAdagrasib·Pemetrexed·Cisplatin·Carboplatin
Mirati Therapeutics Inc.
Phase 3
630
Cheongju-si, Namdong-gu, Yangsan, Busan, Seoul
2025-04-24
Recruiting
Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis
NCT06880770Severe Hypertriglyceridemia
DrugPlozasiran
Arrowhead Pharmaceuticals
Phase 3
288
Seongnam-si, Jeonju, Busan, Sejong, Seoul
2025-04-24
By invitation
To Evaluate the Efficacy and Safety of Co-administrated HODO-2224-1 and HODO-2224-2 in Patients With Essential Hypertension and Primary Hypercholesterolemia
NCT06646354Hypertension, Primary Hypercholesterolaemia
Hyundai Pharm
Phase 3
125
Seoul
2025-04-22
Recruiting
Further Lipid-Lowering With PCSK9 Inhibitors for Cardiovascular Outcomes in High-Risk Coronary Plaques Assessed by CT Angiography
NCT06863545Coronary Artery Disease, CT Angiography, PCSK9, Cardiovascular Events
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
3,596
Seoul
2025-04-22
Recruiting
A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors
NCT07172802Advanced Solid Tumor, Metastatic Solid Tumor, Non-small Cell Lung Cancer (NSCLC), Head and Neck (HNSCC)
GI Innovation, Inc.
Phase 1/2
102
Seoul
2025-04-22
Not yet open
A Study to Compare PK/PD Characteristics and Safety Profiles Between AD-120 and AD-120A
NCT06916130Gastroesophageal Reflux Disease (GERD)
Addpharma Inc.
Phase 1
48
Seoul
2025-04-21
Recruiting
Safety and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectable Hepatocellular Carcinoma
NCT06911255Hepatocellular Carcinoma (HCC), Unresectable Hepatocellular Carcinoma
DrugsTremelimumab·Durvalumab
Yoon Jun Kim
Phase 1/2
24
Seoul
2025-04-18
Recruiting
Post Marketing Study on Pluvicto in Korea
NCT06514521Metastatic Castration-resistant Prostate Cancer
Novartis Pharmaceuticals
Observational
278
Seongnam-si, Suwon, Busan, Gyeonggi-do, Seoul, Jeollanam
2025-04-18
Recruiting
A Study Comparing Immunotherapy Alone Versus Immunotherapy Combined With Radiotherapy in Patients With Hepatocellular Carcinoma (HCC) With Vascular Invasion
NCT06828380Advanced Hepatocellular Carcinoma (HCC)
National Cancer Center, Korea
Phase 2
128
Goyang, Seoul
2025-04-15
Recruiting
Postoperative Vocal Cord Palsy Between Double-lumen Endobronchial Tube and Bronchial Blocker for Robot-assisted Esophagectomy
NCT06897501One Lung Ventillation (OLV)
Samsung Medical Center
Not applicable
202
Seoul
2025-04-14
Recruiting
Imjudo & Imfinzi PMS
NCT06544629Hepatocellular Carcinoma
AstraZeneca
Observational
246
Busan, Goyang, Seongnam, Seoul, Suwon
2025-04-14
Recruiting
Effect of Untact Upper Extremity Rehabilitation Using Smart Glove for Late Subacute and Chronic Patients With Brain Disorder
NCT06837324Brain Disorder, Home Based Rehabilitation
Samsung Medical Center
Not applicable
40
Seoul
2025-04-11
Recruiting
External Validation of Prediction Algorithm Using Non-invasive Monitoring Device for Intraoperative Hypotension
NCT06897514Hypotension During Surgery
Samsung Medical Center
Observational
200
Seoul
2025-04-11
Recruiting
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
NCT06906341Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms, Endometrial Cancer
DrugsNab-paclitaxel /m^2·Relacorilant·Bevacizumab
Corcept Therapeutics
Phase 2
270
Seoul, Gyeonggi-do
2025-04-11
Recruiting
A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
NCT06846671CLL, Chronic Lymphocytic Leukemia
DrugsIdelalisib·Tacabrutideg·Bendamustine·Venetoclax
BeOne Medicines
Phase 3
250
Seogu, Junggu, IlsandongGu GoyangSi, HwasunGun, GangnamGu, SeochoGu, Seoul
2025-04-10
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
NCT06868277Carcinoma, Non-Small Cell Lung
DrugsRilvegostomig·Keytruda·Pembrolizumab
AstraZeneca
Phase 3
830
Jinju, Seoul
2025-04-10
Recruiting
A Randomized, Double-blind, Multi-center, Active-controlled, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of THP-00101, THP-00102, and THP-00103 in Subjects With T2DM and Essential Hypertension
NCT06647745Type 2 Diabetes, Hypertension
THPharm Corp.
Phase 3
221
Seoul
2025-04-10
Recruiting
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
NCT06824467Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
DrugsSteroid mouthwash (dexamethasone·Mvasi·Acetaminophen·Avastin
Merck Sharp & Dohme LLC
Phase 3
770
Goyang-si, Seodaemun-Gu, Songpa-gu, Seoul
2025-04-09
Recruiting
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
NCT06790693Breast Cancer
DrugsCDK4/6i·Inavolisib·Letrozole
Hoffmann-La Roche
Phase 3
450
Daegu, Dongnam-gu, Cheonan-si, Goyang-si, Seongnam-si, Seoul
2025-04-09
Recruiting
A Phase 3 Study to Evaluate the Safety and Efficacy of CKD-843 in Male Patients With Androgenetic Alopecia
NCT06916793Androgenetic Alopecia
DrugDutasteride
Chong Kun Dang Pharmaceutical
Phase 3
288
Seoul
2025-04-08
Recruiting
Respiratory Virus Infections in Acute Heart Failure
NCT06967441Acute Heart Failure Syndrome
Minjae Yoon
Observational
360
Seongnam-si, Seoul
2025-04-07
Active, closed
Evaluation of a Generative AI-Based Voice Documentation System for Patient-Clinician Communication in the Emergency Department and Its Impact on Clinical Workflow Efficiency and Usability
NCT07637591Ambient AI System, Emergency Department, Generative ai
Samsung Medical Center
Not applicable
36
Seoul
2025-04-07
Recruiting
A Phase Ib/II Trial of Neoadjuvant Zolbetuximab Plus Docetaxel, Oxaliplatin and S-1 Chemotherapy in Patients With Locally Advanced Gastric Cancer
NCT06732856Stomach Neoplasm, Gastric (Stomach) Cancer
DrugsZolbetuximab·Tegafur·Docetaxel·Oxaliplatin
Asan Medical Center
Phase 1/2
57
Seoul
2025-04-04
Recruiting
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
NCT06801834Extensive Stage Small Cell Lung Cancer (ES-SCLC)
DrugsAmrubicin·Lurbinectedin·Topotecan·Sacituzumab Govitecan
Gilead Sciences
Phase 3
695
Changwon-Si, Gwangju, Seongbuk-Gu, Seongnam, Seoul, Suwon, Ulsan
2025-04-04
Recruiting
A Study to Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction Cancer.
NCT06902545Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
DrugZolbetuximab
Astellas Pharma Korea, Inc.
Observational
377
Goyang-si, Suwon, Yangsan, Hwasun Gun, Daejeon, Seoul
2025-04-03
Recruiting
Effect of Enavogliflozin on Recurrence of Atrial Fibrillation After Catheter Ablation
NCT06528262Atrial Fibrillation
DrugEnavogliflozin
Yonsei University
Phase 4
390
Seoul
2025-04-03
Recruiting
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
NCT06726148Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Extensive-stage Small Cell Lung Cancer
DrugsRibociclib·Fulvestrant
Novartis Pharmaceuticals
Phase 1/2
280
Seoul
2025-04-03
Recruiting
Developing an Ecological and Tailored Nutritional Intervention to Improve Quality of Life in Esophageal Cancer Survivors
NCT07024849Esophageal Cancer
Samsung Medical Center
Not applicable
30
Seoul
2025-04-03
Recruiting
A Safety and Pharmacokinetics Study of RC220 Combined With Doxorubicin in Adult Participants With Solid Tumours.
NCT06815575Solid Tumours, Advanced Solid Tumours
DrugsAdriamycin·Doxorubicin
Racura Oncology Ltd
Phase 1
53
Seoul
2025-04-02
Recruiting
Global Collaborative Research on Establishing a Korean Cognitive Aging Cohort
NCT07485387Mild Cognitive Impairment (MCI), Dementia Alzheimer Type, Chronic Pain, Depression - Major Depressive Disorder
Korea University
Observational
180
Seoul
2025-04-01
Recruiting
Phase II Clinical Trial to Evaluate the Efficacy and Safety of NV01-A02 in Children With Autism Spectrum Disorder
NCT06951854Autism Spectrum Disorder (ASD
Neuroventi Inc.
Phase 2
105
Seoul
2025-04-01
Recruiting
Effect of Untact Upper Extremity Rehabilitation Using a Smart Board for Late Subacute and Chronic Patients With Brain Disorder
NCT06837363Home Based Rehabilitation, Brain Disorder
Samsung Medical Center
Not applicable
40
Seoul
2025-04-01
By invitation
Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP
NCT06859099Polyneuropathy, Inflammatory Demyelinating, Chronic
DrugRiliprubart
Sanofi
Phase 3
300
Seoul
2025-04-01
Recruiting
A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata
NCT06873945Alopecia Areata
DrugsLitfulo·Ritlecitinib
Pfizer
Phase 3
674
Cheonan-si, Jeonju, Seongnam, Busan, Seoul, Daegu
2025-04-01
Recruiting
A Study to Compare to PK Characteristics and Safety Profiles Between PA-111 and PA-111A
NCT06932705Mixed Dyslipidemia
DrugPA-111
Addpharma Inc.
Phase 1
48
Seoul
2025-04
Recruiting
Ilaris NIS in Korea
NCT06838143Hereditary Periodic Fever Syndromes, Cryopyrin-associated Periodic Syndromes (CAPS), Colchicine Resistance Familial Mediterranean Fever (crFMF), TNF Receptor Associated Periodic Syndrome (TRAPS)
Novartis Pharmaceuticals
Observational
25
Seoul
2025-03-29
Recruiting
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
NCT06989112Endometrial Cancer
DrugsTaxotere·Rilvegostomig·Paraplatin·Taxol
AstraZeneca
Phase 3
600
Goyang-si, Seoul, Suwon
2025-03-27
Recruiting
First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours
NCT06795022Hepatocellular Carcinoma
AstraZeneca
Phase 1/2
304
Seoul
2025-03-27
Recruiting
A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
NCT06644781Esophageal Squamous Cell Carcinoma
DrugsIfinatamab Deruxtecan·Irinotecan·Docetaxel·Paclitaxel
Daiichi Sankyo
Phase 3
510
Daegu, Goyang-si, Hwasun-gun, Incheon, Seongnam-si, Seoul
2025-03-27
Recruiting
Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids
NCT06932263Asthma
DrugTozorakimab
AstraZeneca
Phase 2
540
Cheongju-si, Daegu, Seoul
2025-03-26
Recruiting
A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)
NCT06818643Advanced Solid Tumors, Malignant Neoplasm
DrugMK-3120
Merck Sharp & Dohme LLC
Phase 1/2
270
Seoul
2025-03-25
Active, closed
CART-BP Prospective Study for Hypertension Control
NCT07454148Hypertension
Korea University Anam Hospital
Not applicable
288
Seoul
2025-03-25
Recruiting
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
NCT06797635Breast Neoplasms, Breast Cancer
DrugsEpirubicin Hydrochloride·Patritumab deruxtecan·Doxorubicin Hydrochloride·Olaparib
Merck Sharp & Dohme LLC
Phase 2
372
Seoul
2025-03-20
Active, closed
A Study of Navenibart in Participants With Hereditary Angioedema
NCT06842823Hereditary Angioedema (HAE)
DrugNavenibart
Astria Therapeutics, Inc.
Phase 3
157
Seoul, Yangcheon, Seongnam-si
2025-03-20
Recruiting
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
NCT06819007Ovarian Cancer
DrugsTrastuzumab deruxtecan·Bevacizumab
Daiichi Sankyo
Phase 3
582
Daegu, Goyang-si, Seongnam-si, Seoul
2025-03-19
Recruiting
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
NCT06883305Chronic Obstructive Pulmonary Disease (COPD)
DrugTezepelumab
AstraZeneca
Phase 3
990
Anyang-si, Daegu, Iksan-si, Jeonju, Seoul, Uijeongbu-si, Wลnju
2025-03-18
Active, closed
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
NCT06858878Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
DrugMaridebart cafraglutide
Amgen
Phase 3
1,105
Ansan-si, Gyeonggi-do, Daegu, Seongnam-si, Gyeonggi-do, Seoul, Wonju-si, Gangwon-do
2025-03-17
Recruiting
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
NCT06819878Moderately to Severely Active Crohns Disease
DrugAfimkibart
Hoffmann-La Roche
Phase 3
600
Busan, Daegu, Daejeon, Gangwon-do, Guri-si, Seoul
2025-03-17
Rows per page Showing 801–900 of 2820
Previous 7 8 9 10 11 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a South Korean investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 29 September 2026. https://priyalifescience.com/clinical-trials-south-korea/city/seoul?page=9

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in South Korea and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 3,364 studies in total at the last sync on 26 Sep 2026, 19:49 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 2,820 of those studies with a site in Seoul.

How many clinical trials are recruiting in Seoul?

1,518 of the 2,820 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:49 UTC sync. A further 209 have not yet opened recruitment, 1,015 are active but closed to new participants, and 78 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.